{"title":"免疫疗法治疗阿尔茨海默病的疗效和安全性比较：随机对照试验的网络荟萃分析","authors":"Ching-Hui Su, Ying-Tzu Chang, Huan-Shu Tseng, Chan-Yen Kuo, Jin-Hua Chen, Po- Yu Chien, Yao-Jen Chang, Chin-Chuan Hung","doi":"10.1016/j.clinme.2025.100336","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) remains a major challenge due to limited effective therapies. Moreover, direct comparisons between newly developed and symptomatic drugs are lacking. This network meta-analysis aimed to compare the efficacy and safety of immunotherapies for AD.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov was conducted for randomised controlled trials (RCTs) up to 29 June 2024. Eligible studies included adults with AD receiving immunotherapy versus placebo or symptomatic treatment.</p><p><strong>Results: </strong>Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale-Sum of Boxes P-scores: 0.88 and 0.77) and daily activities (Alzheimer's Disease Cooperative Study-Activities of Daily Living P-scores: 0.85 and 0.90), based on network meta-analysis findings.</p><p><strong>Conclusions: </strong>Anti-Aβ mAbs, particularly donanemab and lecanemab, demonstrated superior efficacy over other immunotherapies in slowing cognitive deterioration, supporting their role in AD management.</p><p><strong>Prospero registration number: </strong>CRD42023461680.</p>","PeriodicalId":10492,"journal":{"name":"Clinical Medicine","volume":" ","pages":"100336"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: a network meta-analysis of randomized controlled trials.\",\"authors\":\"Ching-Hui Su, Ying-Tzu Chang, Huan-Shu Tseng, Chan-Yen Kuo, Jin-Hua Chen, Po- Yu Chien, Yao-Jen Chang, Chin-Chuan Hung\",\"doi\":\"10.1016/j.clinme.2025.100336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alzheimer's disease (AD) remains a major challenge due to limited effective therapies. Moreover, direct comparisons between newly developed and symptomatic drugs are lacking. This network meta-analysis aimed to compare the efficacy and safety of immunotherapies for AD.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov was conducted for randomised controlled trials (RCTs) up to 29 June 2024. Eligible studies included adults with AD receiving immunotherapy versus placebo or symptomatic treatment.</p><p><strong>Results: </strong>Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale-Sum of Boxes P-scores: 0.88 and 0.77) and daily activities (Alzheimer's Disease Cooperative Study-Activities of Daily Living P-scores: 0.85 and 0.90), based on network meta-analysis findings.</p><p><strong>Conclusions: </strong>Anti-Aβ mAbs, particularly donanemab and lecanemab, demonstrated superior efficacy over other immunotherapies in slowing cognitive deterioration, supporting their role in AD management.</p><p><strong>Prospero registration number: </strong>CRD42023461680.</p>\",\"PeriodicalId\":10492,\"journal\":{\"name\":\"Clinical Medicine\",\"volume\":\" \",\"pages\":\"100336\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clinme.2025.100336\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinme.2025.100336","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: a network meta-analysis of randomized controlled trials.
Background: Alzheimer's disease (AD) remains a major challenge due to limited effective therapies. Moreover, direct comparisons between newly developed and symptomatic drugs are lacking. This network meta-analysis aimed to compare the efficacy and safety of immunotherapies for AD.
Methods: A systematic search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov was conducted for randomised controlled trials (RCTs) up to 29 June 2024. Eligible studies included adults with AD receiving immunotherapy versus placebo or symptomatic treatment.
Results: Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale-Sum of Boxes P-scores: 0.88 and 0.77) and daily activities (Alzheimer's Disease Cooperative Study-Activities of Daily Living P-scores: 0.85 and 0.90), based on network meta-analysis findings.
Conclusions: Anti-Aβ mAbs, particularly donanemab and lecanemab, demonstrated superior efficacy over other immunotherapies in slowing cognitive deterioration, supporting their role in AD management.
期刊介绍：
Clinical Medicine is aimed at practising physicians in the UK and overseas and has relevance to all those managing or working within the healthcare sector.
Available in print and online, the journal seeks to encourage high standards of medical care by promoting good clinical practice through original research, review and comment. The journal also includes a dedicated continuing medical education (CME) section in each issue. This presents the latest advances in a chosen specialty, with self-assessment questions at the end of each topic enabling CPD accreditation to be acquired.
ISSN: 1470-2118 E-ISSN: 1473-4893 Frequency: 6 issues per year
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
